Navigation Links
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:5/21/2008

,781 $ 2,389 $ 1,161

Marketing and business

development 1,742 1,504 511 375

General and administrative 2,903 1,860 829 680

Operating loss 11,045 8,145 3,729 2,216

Financial expenses (income),

net 3,616 (538) 149 (200)

Net loss $ 14,661 $ 7,607 $ 3,878 $ 2,016

Basic and diluted net loss

per Ordinary share $ 1.32 $ 2.98 $ 0.33 $ 0.23

Weighted average number of

Ordinary shares used to

compute basic and diluted

net loss per Ordinary share 11,142,149 2,551,860 11,920,401 8,874,841

Contact: Media

Rachel Spielman

T: +1-212-583-2714

E: media@rosettagenomics.com

Investors

Ron Kamienchick

T: +1-646-509-1893

E: investors@rosettagenomics.com

------

Rosetta Genomics Reports First Quarter 2008 Financial Results

First Diagnostic Test Based on Company's microRNA Technology Submitted for Regulatory Approval to the New York State Department of Health by Columbia University Medical CenterAdditional West Coast Clinical Laboratory to Validate and Offer Tests Based on Rosetta Genomics' microRNA TechnologyTwo Additional microRNA-Related Patents Allowed

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, May 21 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading molecular diagnostics company, reported today its consolidated financial results for the quarter ended March 31, 2008 and busin
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3HOWARU 28R 29 Protect Clinically Shown to Reduce the Incidence and Severity of Cold and Flu Symptoms in Children 52951 1HOWARU 28R 29 Protect Clinically Shown to Reduce the Incidence and Severity of Cold and Flu Symptoms in Children 52951 2Humanitas Designated as Approved Provider by California Board of Registered Nursing for Continuing Education Course Credit and Units 52948 1Humanitas Designated as Approved Provider by California Board of Registered Nursing for Continuing Education Course Credit and Units 52948 2Humanitas Designated as Approved Provider by California Board of Registered Nursing for Continuing Education Course Credit and Units 52948 3TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 1TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 2TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 3TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 52945 4